{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:01:32Z","timestamp":1790676092276,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.leukres.2010.02.004","type":"journal-article","created":{"date-parts":[[2010,4,11]],"date-time":"2010-04-11T04:24:09Z","timestamp":1270959849000},"page":"899-905","source":"Crossref","is-referenced-by-count":156,"title":["The DNA demethylating agent 5-aza-2\u2032-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells"],"prefix":"10.1016","volume":"34","author":[{"given":"Maika","family":"Almstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Blagitko-Dorfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Duque-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Karbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.02.004_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2010.02.004_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.2001.02933.x","article-title":"Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2\u2032-deoxycytidine","volume":"114","author":"L\u00fcbbert","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.02.004_bib3","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.02.004_bib4","first-page":"3493","article-title":"Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2\u2032-deoxycytidine as a possible mechanism of chemotherapeutic action","volume":"43","author":"Wilson","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib5","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","article-title":"Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2\u2032-deoxycytidine (decitabine) treatment","volume":"100","author":"Daskalakis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.02.004_bib6","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2010.02.004_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00277-005-0004-1","article-title":"In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies","volume":"84","author":"Hackanson","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.02.004_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.seminoncol.2005.07.024","article-title":"Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents","volume":"32","author":"Claus","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2010.02.004_bib9","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"key":"10.1016\/j.leukres.2010.02.004_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcp.10215","article-title":"Cancer\/testis-associated genes: identification, expression profile, and putative function","volume":"194","author":"Zendman","year":"2003","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.leukres.2010.02.004_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-0897.1998.tb00409.x","article-title":"Major histocompatibility complex expression on human, male germ cells: a review","volume":"40","author":"Fiszer","year":"1998","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.leukres.2010.02.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib13","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1073\/pnas.97.9.4760","article-title":"Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses","volume":"97","author":"J\u00e4ger","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.02.004_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1440-1711.2006.01446.x","article-title":"Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1","volume":"84","author":"Nicholaou","year":"2006","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.leukres.2010.02.004_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature03440","article-title":"The DNA sequence of the human X chromosome","volume":"434","author":"Ross","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2010.02.004_bib17","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1073\/pnas.93.14.7149","article-title":"The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation","volume":"93","author":"De Smet","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.02.004_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.65.1.18","article-title":"Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2\u2032-deoxycytidine","volume":"65","author":"Karpf","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.leukres.2010.02.004_bib19","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2032-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","article-title":"Sequential 5-Aza-2\u2032-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1","volume":"24","author":"Weiser","year":"2001","journal-title":"J Immunother (1991)"},{"key":"10.1016\/j.leukres.2010.02.004_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00262-008-0582-6","article-title":"Treatment of ovarian cancer cell lines with 5-aza-2\u2032-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules","volume":"58","author":"Adair","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.leukres.2010.02.004_bib22","first-page":"2690","article-title":"5-Aza-2\u2032-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications","volume":"8","author":"Coral","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.leu.2402278","article-title":"MAGE-A genes are not expressed in human leukemias","volume":"15","author":"Chambost","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.02.004_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjc.6690824","article-title":"Expression of testicular genes in haematological malignancies","volume":"81","author":"Lim","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0145-2126(02)00230-8","article-title":"Expression of serologically identified tumor antigens in acute leukemias","volume":"27","author":"Niemeyer","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib26","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1182\/blood-2002-11-3458","article-title":"5-Aza-2\u2032-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?","volume":"101","author":"Sigalotti","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.02.004_bib27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1189\/jlb.0106005","article-title":"Inhibitors of DNA methylation and histone deacetylation independently relieve AML1\/ETO-mediated lysozyme repression","volume":"80","author":"Claus","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.leukres.2010.02.004_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<818::AID-IJC10>3.0.CO;2-W","article-title":"Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes","volume":"86","author":"Riker","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib29","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients","volume":"103","author":"J\u00e4ger","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2010.02.004_bib30","first-page":"12","article-title":"Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51","volume":"2","author":"J\u00e4ger","year":"2002","journal-title":"Cancer Immun"},{"key":"10.1016\/j.leukres.2010.02.004_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2010.02.004_bib32","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib33","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cncr.21796","article-title":"Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2\u2032-deoxycytidine retreatment in high-risk myelodysplasia patients","volume":"106","author":"R\u00fcter","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(84)90900-0","article-title":"Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2\u2032-deoxycytidine","volume":"2","author":"Pinto","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2010.02.004_bib35","first-page":"4645","article-title":"Multiple hypermethylated genes are potential in vivo targets of demethylating agents","volume":"101","author":"L\u00fcbbert","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.02.004_bib36","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","author":"L\u00fcbbert","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.02.004_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.leukres.2006.03.003","article-title":"Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine","volume":"31","author":"Graef","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/bmt.2008.400","article-title":"Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome","volume":"43","author":"De Padua Silva","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.02.004_bib39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bmt.2009.64","article-title":"Non-intensive treatment with low-dose 5-aza-2\u2032-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML patients","volume":"44","author":"L\u00fcbbert","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.02.004_bib40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/cncr.11184","article-title":"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias","volume":"97","author":"de Lima","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.02.004_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coi.2006.07.005","article-title":"Immunotherapeutic peptide vaccination with leukemia-associated antigens","volume":"18","author":"Rusakiewicz","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.leukres.2010.02.004_bib42","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.02.004_bib43","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1158\/0008-5472.CAN-06-2986","article-title":"5-AZA-2\u2032-deoxycytidine in cancer immunotherapy: a mouse to man story","volume":"67","author":"Coral","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","article-title":"De novo induction of a cancer\/testis antigen by 5-aza-2\u2032-deoxycytidine augments adoptive immunotherapy in a murine tumor model","volume":"66","author":"Guo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib45","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-06-0669","article-title":"Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura","volume":"12","author":"Schrump","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2010.02.004_bib46","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/MCB.6.11.4122","article-title":"Active X chromosome DNA is unmethylated at eight CCGG sites clustered in a guanine-plus-cytosine-rich island at the 5\u2032 end of the gene for phosphoglycerate kinase","volume":"6","author":"Keith","year":"1986","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.leukres.2010.02.004_bib47","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1038\/sj.onc.1209678","article-title":"Epigenetic regulation of X-linked cancer\/germline antigen genes by DNMT1 and DNMT3b","volume":"25","author":"James","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2010.02.004_bib48","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/hmg\/ddl163","article-title":"The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes","volume":"15","author":"Koslowski","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.leukres.2010.02.004_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccr.2004.06.023","article-title":"Preferential response of cancer cells to zebularine","volume":"6","author":"Cheng","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2010.02.004_bib50","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/ijc.23407","article-title":"The DNA demethylating agent 5-aza-2\u2032-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma","volume":"122","author":"Natsume","year":"2008","journal-title":"Int J Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T21:21:25Z","timestamp":1544563285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0145212610000822"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.02.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}